2023
Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas
Ly C, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Frontiers In Oncology 2023, 12: 1077226. PMID: 36686728, PMCID: PMC9853390, DOI: 10.3389/fonc.2022.1077226.Peer-Reviewed Original ResearchMelanoma-specific mortalityElevated mitotic rateLymph node positivityMitoses/Mitotic rateT2 tumorsNode positivityThin melanomasSentinel lymph node positivityImportant prognostic factorSingle academic centerPrimary cutaneous melanomaLow mitotic ratePositive SLNNon-ulcerated lesionsSLN biopsyT4 tumorsPatient demographicsPrognostic factorsSLN positivityRetrospective reviewTumor characteristicsBreslow thicknessCutaneous melanomaT category
2022
Indoor Versus Outdoor: Does Occupational Sunlight Exposure Increase Melanoma Risk? A Systematic Review
Maduka R, Tai K, Gonsai R, DeWalt N, Chetty A, Brackett A, Olino K, Schneider E, Ahuja V. Indoor Versus Outdoor: Does Occupational Sunlight Exposure Increase Melanoma Risk? A Systematic Review. Journal Of Surgical Research 2022, 283: 274-281. PMID: 36423476, DOI: 10.1016/j.jss.2022.10.025.Peer-Reviewed Original ResearchConceptsCutaneous melanomaSystematic reviewOutdoor occupationsGrading of RecommendationsChronic occupational exposureRetrospective case controlInternational Prospective RegisterNew cancer casesMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsInitial database searchFull-text screeningCutaneous melanoma developmentEvidence certaintyCohort studyScreening recommendationsCommon cancerRisk factorsStudy protocolProspective RegisterCase ascertainmentCancer casesOccupational exposureStudy qualityCase control
2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival